Want to see DERM full AI Analyst Report?
DERM Stock Chart & Stats
$6.37
$0.18(2.91%)
At close: 4:00 PM EDT
$6.37
$0.18(2.91%)
Day’s Range― - ―
52-Week Range$4.31 - $9.56
Previous Close$6.37
Volume133.76K
Average Volume (3M)293.66K
Market Cap
$211.40M
Enterprise Value$194.55
Total Cash (Recent Filing)$25.64M
Total Debt (Recent Filing)$25.54M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding22,224,396
10 Day Avg. Volume156,486
30 Day Avg. Volume293,661
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)5.93
Price to Sales (P/S)3.05
P/FCF Ratio-15.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$13.50Price Target Upside111.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)$82.61M
Bulls Say, Bears Say
Bulls Say
Commercial GrowthStrong revenue, prescription and prescriber growth indicates expanding product adoption and commercial reach. Continued demand for Amrozi can support recurring prescription revenue and improve operating leverage as the sales platform scales.
Improving ProfitabilityHigh gross margins and sharply reduced losses show improving product economics and cost absorption. Positive EBITDA provides evidence that revenue growth is beginning to translate into operating leverage, although GAAP profitability is not yet established.
Commercial Platform ExpansionBroader payer access, additional field coverage and a new dermatology product strengthen the company’s commercialization platform. These investments can expand prescribing opportunities and diversify future growth beyond current products.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow means the business has not yet converted growth into internally funded liquidity. Continued cash burn could limit commercial investment flexibility and increase reliance on its existing cash balance or external financing.
Payer Access FrictionLimited single-step or better coverage can slow prescription conversion, increase authorization burdens and constrain realized pricing. Growth and ASP expansion therefore remain dependent on lengthy payer negotiations and successful downstream plan execution.
Balance Sheet And Return PressureCurrent leverage appears manageable, but negative returns on equity and a history of higher debt dependence reflect unresolved earnings pressure. The balance sheet should strengthen only if management delivers sustained profitability and cash generation.
Journey Medical Corp News
DERM FAQ
What was Journey Medical Corporation’s price range in the past 12 months?
Journey Medical Corporation lowest stock price was $4.31 and its highest was $9.55 in the past 12 months.
What is Journey Medical Corporation’s market cap?
Journey Medical Corporation’s market cap is $211.40M.
When is Journey Medical Corporation’s upcoming earnings report date?
Journey Medical Corporation’s upcoming earnings report date is Nov 11, 2026 which is in 81 days.
How were Journey Medical Corporation’s earnings last quarter?
Journey Medical Corporation released its earnings results on Aug 12, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.012.
Is Journey Medical Corporation overvalued?
According to Wall Street analysts Journey Medical Corporation’s price is currently Undervalued.
Does Journey Medical Corporation pay dividends?
Journey Medical Corporation does not currently pay dividends.
What is Journey Medical Corporation’s EPS estimate?
Journey Medical Corporation’s EPS estimate is 0.02.
How many shares outstanding does Journey Medical Corporation have?
Journey Medical Corporation has 22,224,396 shares outstanding.
What happened to Journey Medical Corporation’s price movement after its last earnings report?
Journey Medical Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went up 3.421%.
Which hedge fund is a major shareholder of Journey Medical Corporation?
Currently, no hedge funds are holding shares in DERM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Journey Medical Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (111.93% Upside)
$13.50 (111.93% Upside)
Blogger Sentiment
Bullish
DERM Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.19%
Trailing 12-Months
Company Description
Journey Medical Corporation
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
DERM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial momentum—notably strong top-line growth (total revenue +23% YoY), robust Amrozi prescription growth (≈20% sequential), expanding prescriber footprint (>40% increase since 2025 year-end), positive EBITDA and materially narrowed GAAP losses—while also acknowledging remaining headwinds around payer friction (only ~38% high-quality formulary coverage), some product-level softness (QBREXZA in the quarter), and timing uncertainty for international out-licensing. Management highlighted continued investments (new reps, marketing, a new product launch) to capitalize on momentum. On balance, the positive operational and financial progress substantially outweighs the noted challenges.View all DERM earnings summariesDERM Stock 12 Month Forecast
Average Price Target
$13.50
▲(111.93% Upside)
Technical Analysis
Ownership Overview
19.48% Insiders
14.17% Mutual Funds
32.15% Other Institutional Investors
30.91% Public Companies and
Individual Investors